Institutional shares held 66.8 Million
318K calls
42.4K puts
Total value of holdings $771M
$3.66M calls
$488K puts
Market Cap $544M
47,147,800 Shares Out.
Institutional ownership 141.76%
# of Institutions 183


Latest Institutional Activity in NRIX

Top Purchases

Q1 2025
New York State Common Retirement Fund Shares Held: 52.7K ($607K)
Q1 2025
Rhumbline Advisers Shares Held: 110K ($1.27M)
Q1 2025
Exchange Traded Concepts, LLC Shares Held: 9.15K ($105K)
Q1 2025
Arizona State Retirement System Shares Held: 17.3K ($199K)
Q1 2025
Amalgamated Bank Shares Held: 2.59K ($29.9K)

Top Sells

Q1 2025
Sumitomo Mitsui Trust Holdings, Inc. Shares Held: 756K ($8.72M)
Q1 2025
Victory Capital Management Inc Shares Held: 29.7K ($342K)
Q1 2025
Massachusetts Financial Services CO Shares Held: 43K ($496K)
Q1 2025
Gamma Investing LLC Shares Held: 1.18K ($13.6K)
Q1 2025
Sg Americas Securities, LLC Shares Held: 21.3K ($245K)

About NRIX

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.


Insider Transactions at NRIX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
173K Shares
From 3 Insiders
Exercise of conversion of derivative security 173K shares
Sell / Disposition
222K Shares
From 4 Insiders
Open market or private sale 168K shares
Bona fide gift 54K shares

Track Institutional and Insider Activities on NRIX

Follow Nurix Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NRIX shares.

Notify only if
Any

Insider Trading

Get notified when an Nurix Therapeutics, Inc. insider buys or sells NRIX shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Nurix Therapeutics, Inc.

Track Activities on NRIX